Patent intelligence · US
US 12077785
Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating Krebs cycle and therapeutic uses thereof
Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating Krebs cycle and therapeutic uses thereof
Patent details — US 12077785
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 3, 2024
- Expiration
- Aug 29, 2044
- Applicant
- SOTIO BIOTECH INC.
- Claims
- 23
- CPC classes
- A61K, A61K2239/31, A61K2239/38, A61K2239/53
Quick answer
US 12077785 (Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating Krebs cycle and therapeutic uses thereof) is held by SOTIO BIOTECH INC.. Status: granted. Granted Sep 3, 2024. Expires Aug 29, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- SOTIO BIOTECH INC.
- Grant date
- Expiration
- Claims
- 23
- CPC classes
- A61K, A61K2239/31, A61K2239/38, A61K2239/53, A61K2239/55, A61K35/17
More from SOTIO BIOTECH INC.
Related pharmaceutical patents in our USPTO index.
-
US 12234288
Immunogenic arginase 2 polypeptides
granted -
US 12233103
Indoleamine 2,3-dioxygenase based immunotherapy
granted -
US 12215135
PDL2 compounds
granted -
US 12194081
ARGINASE1 polypeptides
granted -
US 12187782
PDL1 peptides for use in cancer vaccines
granted -
US 11981944
Immunogenic arginase peptides
granted -
US 11878053
Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereof
granted
Frequently asked questions
What is US patent 12077785?
US 12077785 (Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating Krebs cycle and therapeutic uses thereof) is held by SOTIO BIOTECH INC.. Status: granted. Granted Sep 3, 2024. Expires Aug 29, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12077785?
SOTIO BIOTECH INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 21 pharmaceutical patents for this assignee.
When does US 12077785 expire?
Our index shows an expiration date of Aug 29, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.